PMC:7463108 / 105713-107502 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T40 360-364 Body_part denotes bile http://purl.org/sig/ont/fma/fma62971

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T192 360-364 Body_part denotes bile http://purl.obolibrary.org/obo/UBERON_0001970

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T51 242-248 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T52 926-927 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T77414 24-28 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T35911 29-33 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T93114 121-135 Chemical denotes opioid agonist http://purl.obolibrary.org/obo/CHEBI_60606
T82 128-135 Chemical denotes agonist http://purl.obolibrary.org/obo/CHEBI_48705
T50219 137-150 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T84 180-195 Chemical denotes cytochrome P450 http://purl.obolibrary.org/obo/CHEBI_38559
T97276 180-190 Chemical denotes cytochrome http://purl.obolibrary.org/obo/CHEBI_4056
T22765 197-200 Chemical denotes CYP http://purl.obolibrary.org/obo/CHEBI_38559
T14085 220-233 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T55445 249-259 Chemical denotes metabolite http://purl.obolibrary.org/obo/CHEBI_25212
T52742 301-304 Chemical denotes UDP http://purl.obolibrary.org/obo/CHEBI_17659|http://purl.obolibrary.org/obo/CHEBI_58223
T91 490-508 Chemical denotes protease inhibitor http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258
T93 499-508 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T84290 522-532 Chemical denotes atazanavir http://purl.obolibrary.org/obo/CHEBI_37924
T94858 533-542 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T64009 553-556 Chemical denotes CYP http://purl.obolibrary.org/obo/CHEBI_38559
T31065 627-640 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T66339 807-820 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T71773 866-876 Chemical denotes atazanavir http://purl.obolibrary.org/obo/CHEBI_37924
T59554 994-997 Chemical denotes CYP http://purl.obolibrary.org/obo/CHEBI_38559
T96679 1086-1095 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T13987 1100-1119 Chemical denotes protease inhibitors http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258
T71378 1109-1119 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T12801 1267-1276 Chemical denotes efavirenz http://purl.obolibrary.org/obo/CHEBI_119486
T21399 1281-1291 Chemical denotes nevirapine http://purl.obolibrary.org/obo/CHEBI_63613
T63149 1299-1302 Chemical denotes CYP http://purl.obolibrary.org/obo/CHEBI_38559
T42314 1358-1367 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T83783 1457-1466 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T110 1501-1510 Chemical denotes efavirenz http://purl.obolibrary.org/obo/CHEBI_119486
T76240 1514-1524 Chemical denotes nevirapine http://purl.obolibrary.org/obo/CHEBI_63613
T112 1612-1621 Chemical denotes Oxycodone http://purl.obolibrary.org/obo/CHEBI_7852
T10495 1649-1668 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T70158 1649-1658 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T42172 1659-1668 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T41667 1681-1690 Chemical denotes oxycodone http://purl.obolibrary.org/obo/CHEBI_7852
T51574 1735-1739 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3595 180-213 Gene denotes cytochrome P450 (CYP) 3A4 and 2C8 Gene:1576
3596 301-338 Gene denotes UDP-glucuronosyltransferase (UGT) 1A1 Gene:54658
3597 553-560 Gene denotes CYP 3A4 Gene:1576
3598 565-572 Gene denotes UGT 1A1 Gene:54658
3599 994-1001 Gene denotes CYP 3A4 Gene:1576
3600 1299-1306 Gene denotes CYP 3A4 Gene:1576
3601 137-150 Chemical denotes buprenorphine MESH:D002047
3602 220-233 Chemical denotes buprenorphine MESH:D002047
3603 261-277 Chemical denotes norbuprenorphine MESH:C043585
3604 522-532 Chemical denotes atazanavir MESH:D000069446
3605 533-542 Chemical denotes ritonavir MESH:D019438
3606 627-640 Chemical denotes buprenorphine MESH:D002047
3607 645-661 Chemical denotes norbuprenorphine MESH:C043585
3608 807-820 Chemical denotes buprenorphine MESH:D002047
3609 866-876 Chemical denotes atazanavir MESH:D000069446
3610 913-922 Chemical denotes Methadone MESH:D008691
3611 1086-1095 Chemical denotes methadone MESH:D008691
3612 1267-1276 Chemical denotes efavirenz MESH:C098320
3613 1281-1291 Chemical denotes nevirapine MESH:D019829
3614 1358-1367 Chemical denotes methadone MESH:D008691
3615 1457-1466 Chemical denotes methadone MESH:D008691
3616 1501-1510 Chemical denotes efavirenz MESH:C098320
3617 1514-1524 Chemical denotes nevirapine MESH:D019829
3618 1612-1621 Chemical denotes Oxycodone MESH:D010098
3619 1649-1668 Chemical denotes lopinavir/ritonavir MESH:C558899
3620 1681-1690 Chemical denotes oxycodone MESH:D010098
3621 67-71 Disease denotes ARVs
3622 374-378 Disease denotes ARVs
3623 1391-1417 Disease denotes opioid withdrawal symptoms MESH:D013375

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T20 180-190 http://purl.obolibrary.org/obo/GO_0045158 denotes cytochrome
T21 180-190 http://purl.obolibrary.org/obo/GO_0045157 denotes cytochrome
T22 180-190 http://purl.obolibrary.org/obo/GO_0045156 denotes cytochrome
T23 180-190 http://purl.obolibrary.org/obo/GO_0008121 denotes cytochrome
T24 749-758 http://purl.obolibrary.org/obo/GO_0050890 denotes cognition
T25 1622-1632 http://purl.obolibrary.org/obo/GO_0008152 denotes metabolism

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1330 0-108 Sentence denotes There are several known drug-drug interactions between opioids and ARVs that affect systemic concentrations.
T1331 109-214 Sentence denotes The partial opioid agonist, buprenorphine, is metabolized primarily by cytochrome P450 (CYP) 3A4 and 2C8.
T1332 215-365 Sentence denotes Both buprenorphine and its active metabolite, norbuprenorphine, are glucuronidated by UDP-glucuronosyltransferase (UGT) 1A1 and then excreted in bile.
T1333 366-422 Sentence denotes Several ARVs inhibit or induce these metabolic pathways.
T1334 423-477 Sentence denotes However, not all interactions are clinically relevant.
T1335 478-779 Sentence denotes The boosted protease inhibitor combination, atazanavir/ritonavir, inhibits CYP 3A4 and UGT 1A1, leading to increases in overall systemic exposure of buprenorphine and norbuprenorphine and also results in symptoms of opioid excess, such as increased sedation and impaired cognition (McCance-Katz et al.
T1336 780-786 Sentence denotes 2007).
T1337 787-912 Sentence denotes Dose adjustments of buprenorphine are recommended when initiating therapy with atazanavir to avoid symptoms of opioid excess.
T1338 913-1027 Sentence denotes Methadone is a full opioid substrate with multiple metabolic pathways, including CYP 3A4, 2B6, 2C19, 2C9, and 2D6.
T1339 1028-1120 Sentence denotes Several pharmacokinetic interactions are reported between methadone and protease inhibitors.
T1340 1121-1225 Sentence denotes However, withdrawal symptoms are rare, and therefore, dose adjustments are not recommended (Bruce et al.
T1341 1226-1246 Sentence denotes 2006; Meemken et al.
T1342 1247-1253 Sentence denotes 2015).
T1343 1254-1418 Sentence denotes In contrast, efavirenz and nevirapine induce CYP 3A4, resulting in decreased systemic concentrations of methadone and the development of opioid withdrawal symptoms.
T1344 1419-1563 Sentence denotes To avoid opioid withdrawal, increased methadone dosing is recommended when either efavirenz or nevirapine therapy is initiated (Marzolini et al.
T1345 1564-1583 Sentence denotes 2000; Clarke et al.
T1346 1584-1604 Sentence denotes 2001; Meemken et al.
T1347 1605-1611 Sentence denotes 2015).
T1348 1612-1764 Sentence denotes Oxycodone metabolism is inhibited by lopinavir/ritonavir, increasing oxycodone concentrations as well as the self-reported drug effects (Nieminen et al.
T1349 1765-1782 Sentence denotes 2010; Feng et al.
T1350 1783-1789 Sentence denotes 2017).

2_test

Id Subject Object Predicate Lexical cue
32876803-17643869-62958380 780-784 17643869 denotes 2007
32876803-17109308-62958381 1226-1230 17109308 denotes 2006
32876803-25902733-62958382 1247-1251 25902733 denotes 2015
32876803-10894303-62958383 1564-1568 10894303 denotes 2000
32876803-11298066-62958384 1584-1588 11298066 denotes 2001
32876803-25902733-62958385 1605-1609 25902733 denotes 2015
32876803-20697700-62958386 1765-1769 20697700 denotes 2010
32876803-28579821-62958387 1783-1787 28579821 denotes 2017